Obesity and breast cancer: A clinical biochemistry perspective

Clinical Biochemistry

Volumn 45, Issue 3, 2012, Pages 189-197

  Ray, Amitabha ^a   Cleary, Margot P ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Adiposity; Lab diagnosis; Leptin; Lipids; Neoplasia

Indexed keywords

ALANINE AMINOTRANSFERASE; AROMATASE; C PEPTIDE; C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; FIBROBLAST GROWTH FACTOR; GELATINASE B; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOGEN ACTIVATED PROTEIN KINASE; OLEIC ACID; PROTEIN KINASE B; PROTEIN P53; SCATTER FACTOR; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; TESTOSTERONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; VASCULOTROPIN;

ADIPOSE TISSUE; ASPIRATION BIOPSY; BIOCHEMISTRY; BLOOD; BLOOD COMPONENT; BREAST CANCER; CALORIC INTAKE; CALORIC RESTRICTION; CANCER RISK; DISEASE ASSOCIATION; DYSLIPIDEMIA; EARLY DIAGNOSIS; EXTRACELLULAR MATRIX; HUMAN; HYPERINSULINEMIA; HYPERLEPTINEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LABORATORY DIAGNOSIS; LIFESTYLE MODIFICATION; LIPID PEROXIDATION; MAMMOGRAPHY; MEDLINE; METABOLIC SYNDROME X; NEOVASCULARIZATION (PATHOLOGY); NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; URINE; WHITE ADIPOSE TISSUE;

BIOMEDICAL RESEARCH; BREAST NEOPLASMS; FEMALE; HUMANS; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEPTIN; OBESITY; POSTMENOPAUSE;

EID: 84856502414     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.11.016     Document Type: Review

References (143)

1. Lindgren A.M., Nissinen A.M., Tuomilehto J.O., Pukkala E. Cancer pattern among hypertensive patients in North Karelia, Finland. J Hum Hypertens 2005, 19:373-379.
2. Nicolucci A. Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 2010, 47:87-95.
3. Jee S.H., Kim H.J., Lee J. Obesity, insulin resistance and cancer risk. Yonsei Med J 2005, 46:449-455.
4. Vrieling A., Buck K., Kaaks R., Chang-Claude J. Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis. Breast Cancer Res Treat 2010, 123:641-649.
5. Yang X.R., Chang-Claude J., Goode E.L., Couch F.J., Nevanlinna H., Milne R.L., et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association consortium studies. J Natl Cancer Inst 2011, 103:250-263.
6. Sarkissyan M., Wu Y., Vadgama J.V. Obesity is associated with breast cancer in African-American women but not Hispanic women in South Los Angeles. Cancer 2011, 117:3814-3823.
7. Deglise C., Bouchardy C., Burri M., Usel M., Neyroud-Caspar I., Vlastos G., et al. Impact of obesity on diagnosis and treatment of breast cancer. Breast Cancer Res Treat 2010, 120:185-193.
8. Majed B., Dozol A., Ribassin-Majed L., Senouci K., Asselain B. Increased risk of contralateral breast cancers among overweight and obese women: a time-dependent association. Breast Cancer Res Treat 2011, 126:729-738.
9. Huang P.L. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009, 2:231-237.
10. Haas J.T., Biddinger S.B. Dissecting the role of insulin resistance in the metabolic syndrome. Curr Opin Lipidol 2009, 20:206-210.
11. Agnoli C., Berrino F., Abagnato C.A., Muti P., Panico S., Crosignani P., et al. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study. Nutr Metab Cardiovasc Dis 2010, 20:41-48.
12. Furberg A.S., Veierød M.B., Wilsgaard T., Bernstein L., Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst 2004, 96:1152-1160.
13. Alexopoulos C.G., Blatsios B., Avgerinos A. Serum lipids and lipoprotein disorders in cancer patients. Cancer 1987, 60:3065-3070.
14. Ray A., Sharma B.K., Bahadur A.K., Pasha S.T., Bhadola P., Murthy N.S. Serum lipid profile and its relationship with host immunity in carcinomas of the breast and uterine cervix. Tumori 1997, 83:943-947.
15. Han C., Zhang H.T., Du L., Liu X., Jing J., Zhao X., et al. Serum levels of leptin, insulin, and lipids in relation to breast cancer in China. Endocrine 2005, 26:19-24.
16. Kim Y., Park S.K., Han W., Kim D.H., Hong Y.C., Ha E.H., et al. Serum high-density lipoprotein cholesterol and breast cancer risk by menopausal status, body mass index, and hormonal receptor in Korea. Cancer Epidemiol Biomarkers Prev 2009, 18:508-515.
17. Osaki Y., Taniguchi S.I., Tahara A., Okamoto M., Kishimoto T. Metabolic syndrome and incidence of liver and breast cancers in Japan. Cancer Epidemiol 2011, doi:10.1016/j.canep.2011.03.007 (PubMed ID: 21890443).
18. Rosato V., Bosetti C., Talamini R., Levi F., Montella M., Giacosa A., Negri E., La Vecchia C. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann Oncol 2011, 22:2687-2692.
19. Capasso I., Esposito E., Pentimalli F., Crispo A., Montella M., Grimaldi M., et al. Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience. Cancer Biol Ther 2011, 10:1240-1243.
20. Vona-Davis L., Howard-McNatt M., Rose D.P. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev 2007, 8:395-408.
21. Bowker S.L., Richardson K., Marra C.A., Johnson J.A. Risk of breast cancer after onset of type 2 diabetes: evidence of detection bias in postmenopausal women. Diabetes Care 2011, 34:2542-2544.
22. Liao S., Li J., Wei W., Wang L., Zhang Y., Li J., et al. Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac J Cancer Prev 2011, 12:1061-1065.
23. Wolf I., Sadetzki S., Catane R., Karasik A., Kaufman B. Diabetes mellitus and breast cancer. Lancet Oncol 2005, 6:103-111.
24. Schott S., Schneeweiss A., Sohn C. Breast cancer and diabetes mellitus. Exp Clin Endocrinol Diabetes 2010, 118:673-677.
25. Gallagher E.J., LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 2010, 21:610-618.
26. Rensing K.L., Houttuijn Bloemendaal F.M., Weijers E.M., Richel D.J., Büller H.R., Koolwijk P., et al. Could recombinant insulin compounds contribute to adenocarcinoma progression by stimulating local angiogenesis?. Diabetologia 2010, 53:966-970.
27. Vona-Davis L., Rose D.P. Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev 2009, 20:193-201.
28. Munzberg H. Leptin-signaling pathways and leptin resistance. Forum Nutr 2010, 63:123-132.
29. Almeida-Pititto B.D., Gimeno S.G., Sanudo A., Ribeiro-Filho F.F., Ferreira S.R. Leptin is associated with insulin resistance in Japanese migrants. Metab Syndr Relat Disord 2005, 3:140-146. Japanese-Brazilian Diabetes Study Group.
30. Yun J.E., Kimm H., Jo J., Jee S.H. Serum leptin is associated with metabolic syndrome in obese and nonobese Korean populations. Metabolism 2010, 59:424-429.
31. Samara A., Herbeth B., Aubert R., Berrahmoune H., Fumeron F., Siest G., et al. Sex-dependent associations of leptin with metabolic syndrome-related variables: the Stanislas study. Obesity (Silver Spring) 2010, 18:196-201.
32. Wannamethee S.G., Tchernova J., Whincup P., Lowe G.D., Kelly A., Rumley A., et al. Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis 2007, 191:418-426.
33. Shin M.J., Lee J.H., Jang Y., Park E., Oh J., Chung J.H., et al. Insulin resistance, adipokines, and oxidative stress in nondiabetic, hypercholesterolemic patients: leptin as an 8-epi-prostaglandin F2alpha determinant. Metabolism 2006, 55:918-922.
34. Iikuni N., Lam Q.L., Lu L., Matarese G., La Cava A. Leptin and inflammation. Curr Immunol Rev 2008, 4:70-79.
35. Mistry T., Digby J.E., Desai K.M., Randeva H.S. Leptin and adiponectin interact in the regulation of prostate cancer cell growth via modulation of p53 and bcl-2 expression. BJU Int 2008, 101:1317-1322.
36. Chen C., Chang Y.C., Liu C.L., Chang K.J., Guo I.C. Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1. Breast Cancer Res Treat 2006, 98:121-132.
37. Sirotkin A.V., Grossmann R. Leptin directly controls proliferation, apoptosis and secretory activity of cultured chicken ovarian cells. Comp Biochem Physiol A Mol Integr Physiol 2007, 148:422-429.
38. Minamino T., Orimo M., Shimizu I., Kunieda T., Yokoyama M., Ito T., et al. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat Med 2009, 15:1082-1087.
39. Yahagi N., Shimano H., Matsuzaka T., Sekiya M., Najima Y., Okazaki S., et al. p53 involvement in the pathogenesis of fatty liver disease. J Biol Chem 2004, 279:20571-20575.
40. Geisler J., Haynes B., Ekse D., Dowsett M., Lønning P.E. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. J Steroid Biochem Mol Biol 2007, 104:27-34.
41. Magoffin D.A., Weitsman S.R., Aagarwal S.K., Jakimiuk A.J. Leptin regulation of aromatase activity in adipose stromal cells from regularly cycling women. Ginekol Pol 1999, 70:1-7.
42. Yu W., Gu J.C., Liu J.Z., Wang S.H., Wang Y., Zhang Z.T., et al. Regulation of estrogen receptors alpha and beta in human breast carcinoma by exogenous leptin in nude mouse xenograft model. Chin Med J (Engl) 2010, 123:337-343.
43. Fusco R., Galgani M., Procaccini C., Franco R., Pirozzi G., Fucci L., et al. Cellular and molecular crosstalk between leptin receptor and estrogen receptor-{alpha} in breast cancer: molecular basis for a novel therapeutic setting. Endocr Relat Cancer 2010, 17:373-382.
44. Binai N.A., Damert A., Carra G., Steckelbroeck S., Löwer J., Löwer R., et al. Expression of estrogen receptor alpha increases leptin-induced STAT3 activity in breast cancer cells. Int J Cancer 2010, 127:55-66.
45. Cirillo D., Rachiglio A.M., la Montagna R., Giordano A., Normanno N. Leptin signaling in breast cancer: an overview. J Cell Biochem 2008, 105:956-964.
46. Frankenberry K.A., Skinner H., Somasundar P., McFadden D.W., Vona-Davis L.C. Leptin receptor expression and cell signaling in breast cancer. Int J Oncol 2006, 28:985-993.
47. Hancke K., Grubeck D., Hauser N., Kreienberg R., Weiss J.M. Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat 2010, 119:367-377.
48. Wu M.H., Chou Y.C., Chou W.Y., Hsu G.C., Chu C.H., Yu C.P., et al. Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer 2009, 100:578-582.
49. Han C.Z., Du L.L., Jing J.X., Zhao X.W., Tian F.G., Shi J., et al. Associations among lipids, leptin, and leptin receptor gene Gin223Arg polymorphisms and breast cancer in China. Biol Trace Elem Res 2008, 126:38-48.
50. Macciò A., Madeddu C., Gramignano G., Mulas C., Floris C., Massa D., et al. Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications. J Mol Med 2010, 88:677-686.
51. Cust A.E., Stocks T., Lukanova A., Lundin E., Hallmans G., Kaaks R., et al. The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat 2009, 113:567-576.
52. Kim H.S. Leptin and leptin receptor expression in breast cancer. Cancer Res Treat 2009, 41:155-163.
53. Jardé T., Caldefie-Chézet F., Damez M., Mishellany F., Penault-Llorca F., Guillot J., et al. Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. Oncol Rep 2008, 19:905-911.
54. Koda M., Kanczuga-Koda L., Sulkowska M., Surmacz E., Sulkowski S. Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: effects of preoperative chemotherapy. BMC Cancer 2010, 10:320.
55. Petridou E., Papadiamantis Y., Markopoulos C., Spanos E., Dessypris N., Trichopoulos D. Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes Control 2000, 11:383-388.
56. Falk R.T., Brinton L.A., Madigan M.P., Potischman N., Sturgeon S.R., Malone K.E., et al. Interrelationships between serum leptin, IGF-1, IGFBP3, C-peptide and prolactin and breast cancer risk in young women. Breast Cancer Res Treat 2006, 98:157-165.
57. Harris H.R., Tworoger S.S., Hankinson S.E., Rosner B.A., Michels K.B. Plasma leptin levels and risk of breast cancer in premenopausal women. Cancer Prev Res (Phila) 2011, 4:1449-1456.
58. Ray A., Nkhata K.J., Grande J.P., Cleary M.P. Diet-induced obesity and mammary tumor development in relation to estrogen receptor status. Cancer Lett 2007, 253:291-300.
59. Grossmann M.E., Ray A., Nkhata K.J., Malakhov D.A., Rogozina O.P., Dogan S., et al. Obesity and breast cancer: status of leptin and adiponectin in pathological processes. Cancer Metastasis Rev 2010, 29:641-653.
60. Gonzalez-Perez R.R., Xu Y., Guo S., Watters A., Zhou W., Leibovich S.J. Leptin upregulates VEGF in breast cancer via canonic and non-canonical signalling pathways and NFkappaB/HIF-1alpha activation. Cell Signal 2010, 22:1350-1362.
61. Gonzalez R.R., Cherfils S., Escobar M., Yoo J.H., Carino C., Styer A.K., et al. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem 2006, 281:26320-26328.
62. Rene Gonzalez R., Watters A., Xu Y., Singh U.P., Mann D.R., Rueda B.R., et al. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res 2009, 11:R36.
63. Otvos L., Kovalszky I., Scolaro L., Sztodola A., Olah J., Cassone M., et al. Peptide-based leptin receptor antagonists for cancer treatment and appetite regulation. Biopolymers 2011, 96:117-125.
64. Ray A., Cleary M.P. Leptin as a potential therapeutic target for breast cancer prevention and treatment. Expert Opin Ther Targets 2010, 14:443-451.
65. Cottam D., Fisher B., Ziemba A., Atkinson J., Grace B., Ward D.C., et al. Tumor growth factor expression in obesity and changes in expression with weight loss: another cause of increased virulence and incidence of cancer in obesity. Surg Obes Relat Dis 2010, 6:538-541.
66. Renehan A.G., Frystyk J., Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006, 17:328-336.
67. Rutkowski J.M., Davis K.E., Scherer P.E. Mechanisms of obesity and related pathologies: the macro- and microcirculation of adipose tissue. FEBS J 2009, 276:5738-5746.
68. Vona-Davis L., Rose D.P. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 2007, 14:189-206.
69. Frasca F., Pandini G., Sciacca L., Pezzino V., Squatrito S., Belfiore A., et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008, 114:23-37.
70. Schwertfeger K.L. Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands. Curr Drug Targets 2009, 10:632-644.
71. Huang X., Yang C., Luo Y., Jin C., Wang F., McKeehan W.L. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 2007, 56:2501-2510.
72. Widberg C.H., Newell F.S., Bachmann A.W., Ramnoruth S.N., Spelta M.C., Whitehead J.P., et al. Fibroblast growth factor receptor 1 is a key regulator of early adipogenic events in human preadipocytes. Am J Physiol Endocrinol Metab 2009, 296:E121-E131.
73. Peterson M.C. Circulating transforming growth factor beta-1: a partial molecular explanation for associations between hypertension, diabetes, obesity, smoking and human disease involving fibrosis. Med Sci Monit 2005, 11:RA229-RA232.
74. Glasgow E., Mishra L. Transforming growth factor-beta signaling and ubiquitinators in cancer. Endocr Relat Cancer 2008, 15:59-72.
75. Nakano N., Miyazawa N., Sakurai T., Kizaki T., Kimoto K., Takahashi K., et al. Gliclazide inhibits proliferation but stimulates differentiation of white and brown adipocytes. J Biochem 2007, 142:639-645.
76. Marcus Y., Stern N. Fat cell-derived modulators of vascular cell pathophysiology: the list keeps growing. J Cardiometab Syndr 2006, 1:121-124.
77. Skopková M., Penesová A., Sell H., Rádiková Z., Vlcek M., Imrich R., et al. Protein array reveals differentially expressed proteins in subcutaneous adipose tissue in obesity. Obesity (Silver Spring) 2007, 15:2396-2406.
78. Vacaresse N., Lajoie-Mazenc I., Augé N., Suc I., Frisach M.F., Salvayre R., et al. Activation of epithelial growth factor receptor pathway by unsaturated fatty acids. Circ Res 1999, 85:892-899.
79. Prada P.O., Ropelle E.R., Mourão R.H., de Souza C.T., Pauli J.R., Cintra D.E., et al. EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice. Diabetes 2009, 58:2910-2919.
80. Jamroz-Wiśniewska A., Wójcicka G., Łowicka E., Ksiazek M., Bełtowski J. Transactivation of epidermal growth factor receptor in vascular and renal systems in rats with experimental hyperleptinemia: role in leptin-induced hypertension. Biochem Pharmacol 2008, 75:1623-1638.
81. Saxena N.K., Taliaferro-Smith L., Knight B.B., Merlin D., Anania F.A., O'Regan R.M., et al. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res 2008, 68:9712-9722.
82. Soma D., Kitayama J., Yamashita H., Miyato H., Ishikawa M., Nagawa H. Leptin augments proliferation of breast cancer cells via transactivation of HER2. J Surg Res 2008, 149:9-14.
83. Eisenberg A., Biener E., Charlier M., Krishnan R.V., Djiane J., Herman B., et al. Transactivation of erbB2 by short and long isoforms of leptin receptors. FEBS Lett 2004, 565:139-142.
84. Sheffield L. Malignant transformation of mammary epithelial cells increases expression of leptin and leptin receptor. Endocr Res 2008, 33:111-118.
85. Ray A., Nkhata K.J., Cleary M.P. Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status. Int J Oncol 2007, 30:1499-1509.
86. Menendez J.A., Vellon L., Lupu R. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol 2005, 16:1253-1267.
87. Fiorio E., Mercanti A., Terrasi M., Micciolo R., Remo A., Auriemma A., et al. Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis. BMC Cancer 2008, 8:305.
88. Cleary M.P., Grande J.P., Juneja S.C., Maihle N.J. Diet-induced obesity and mammary tumor development in MMTV-neu female mice. Nutr Cancer 2004, 50:174-180.
89. Khalid S., Hwang D., Babichev Y., Kolli R., Altamentova S., Koren S., et al. Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis. Breast Cancer Res Treat 2010, 122:647-659.
90. Ishizaka N., Ishizaka Y., Toda E., Koike K., Nagai R., Yamakado M. Impact of changes in waist circumference and BMI over one-year period on serum lipid data in Japanese individuals. J Atheroscler Thromb 2009, 16:764-771.
91. Centers for Disease Control and Prevention (CDC) Prevalence of abnormal lipid levels among youths - United States, 1999-2006. MMWR Morb Mortal Wkly Rep 2010, 59:29-33.
92. Oka R., Miura K., Sakurai M., Nakamura K., Yagi K., Miyamoto S., et al. Impacts of visceral adipose tissue and subcutaneous adipose tissue on metabolic risk factors in middle-aged Japanese. Obesity (Silver Spring) 2010, 18:153-160.
93. Shim W.S., Kim H.J., Kang E.S., Ahn C.W., Lim S.K., Lee H.C., et al. The association of total and differential white blood cell count with metabolic syndrome in type 2 diabetic patients. Diabetes Res Clin Pract 2006, 73:284-291.
94. Phillips A.C., Carroll D., Gale C.R., Drayson M., Thomas G.N., Batty G.D. Lymphocyte sub-population cell counts are associated with the metabolic syndrome and its components in the Vietnam Experience Study. Atherosclerosis 2010, 213:294-298.
95. Thomson C.A., Thompson P.A., Wright-Bea J., Nardi E., Frey G.R., Stopeck A. Metabolic syndrome and elevated C-reactive protein in breast cancer survivors on adjuvant hormone therapy. J Womens Health (Larchmt) 2009, 18:2041-2047.
96. Wang C.S., Sun C.F. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J 2009, 32:471-482.
97. Karatela R.A., Sainani G.S. Plasma homocysteine in obese, overweight and normal weight hypertensives and normotensives. Indian Heart J 2009, 61:156-159.
98. Brustolin S., Giugliani R., Félix T.M. Genetics of homocysteine metabolism and associated disorders. Braz J Med Biol Res 2010, 43:1-7.
99. Derosa G., Ferrari I., D'Angelo A., Tinelli C., Salvadeo S.A., Ciccarelli L., et al. Matrix metalloproteinase-2 and - 9 levels in obese patients. Endothelium 2008, 15:219-224.
100. Unal R., Yao-Borengasser A., Varma V., Rasouli N., Labbate C., Kern P.A., et al. Matrix metalloproteinase-9 is increased in obese subjects and decreases in response to pioglitazone. J Clin Endocrinol Metab 2010, 95:2993-3001.
101. Papazoglou D., Papatheodorou K., Papanas N., Papadopoulos T., Gioka T., Kabouromiti G., et al. Matrix metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 levels in severely obese patients: what is the effect of weight loss?. Exp Clin Endocrinol Diabetes 2010, 118:730-734.
102. Groop L.C. Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes Obes Metab 1999, 1(Suppl. 1):S1-S7.
103. Sikaris K.A. The clinical biochemistry of obesity - more than skin deep. Heart Lung Circ 2007, 16(Suppl. 3):S45-S50.
104. Brandenburg D. History and diagnostic significance of C-peptide. Exp Diabetes Res 2008, 2008:576862.
105. Mavian A.A., Miller S., Henry R.R. Managing type 2 diabetes: balancing HbA1c and body weight. Postgrad Med 2010, 122:106-117.
106. Weinberg M.E., Manson J.E., Buring J.E., Cook N.R., Seely E.W., Ridker P.M., et al. Low sex hormone-binding globulin is associated with the metabolic syndrome in postmenopausal women. Metabolism 2006, 55:1473-1480.
107. Cleary M.P., Maihle N.J. The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med 1997, 216:28-43.
108. Rose D.P., Vona-Davis L. Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas 2010, 66:33-38.
109. Gallagher E.J., Leroith D., Karnieli E. Insulin resistance in obesity as the underlying cause for the metabolic syndrome. Mt Sinai J Med 2010, 77:511-523.
110. Feldstein A.E. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis 2010, 30:391-401.
111. Chen P.H., Chen J.D., Lin Y.C. A better parameter in predicting insulin resistance: obesity plus elevated alanine aminotransferase. World J Gastroenterol 2009, 15:5598-5603.
112. Saito T., Nishise Y., Makino N., Haga H., Ishii R., Okumoto K., et al. Impact of metabolic syndrome on elevated serum alanine aminotransferase levels in the Japanese population. Metabolism 2009, 58:1067-1075.
113. Cheng S., Massaro J.M., Fox C.S., Larson M.G., Keyes M.J., McCabe E.L., et al. Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. Diabetes 2010, 59:242-248.
114. Baz-Hecht M., Goldfine A.B. The impact of vitamin D deficiency on diabetes and cardiovascular risk. Curr Opin Endocrinol Diabetes Obes 2010, 17:113-119.
115. Issaq H.J., Waybright T.J., Veenstra T.D. Cancer biomarker discovery: opportunities and pitfalls in analytical methods. Electrophoresis 2011, 32:967-975.
116. Hanash S.M., Baik C.S., Kallioniemi O. Emerging molecular biomarkers - blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol 2011, 8:142-150.
117. Athyros V.G., Tziomalos K., Karagiannis A., Anagnostis P., Mikhailidis D.P. Should adipokines be considered in the choice of the treatment of obesity-related health problems?. Curr Drug Targets 2010, 11:122-135.
118. Bergmann S., Siekmeier R. Influence of smoking and body weight on adipokines in middle aged women. Eur J Med Res 2009, 14(Suppl. 4):21-26.
119. Milewicz A., Jedrzejuk D., Dunajska K., Lwow F. Waist circumference and serum adiponectin levels in obese and non-obese postmenopausal women. Maturitas 2010, 65:272-275.
120. Hansen D., Dendale P., Beelen M., Jonkers R.A., Mullens A., Corluy L., et al. Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients. Eur J Appl Physiol 2010, 109:397-404.
121. Thorand B., Zierer A., Baumert J., Meisinger C., Herder C., Koenig W. Associations between leptin and the leptin/adiponectin ratio and incident Type 2 diabetes in middle-aged men and women: results from the MONICA/KORA Augsburg study 1984-2002. Diabet Med 2010, 27:1004-1011.
122. Ashizawa N., Yahata T., Quan J., Adachi S., Yoshihara K., Tanaka K. Serum leptin-adiponectin ratio and endometrial cancer risk in postmenopausal female subjects. Gynecol Oncol 2010, 119:65-69.
123. Inoue M., Maehata E., Yano M., Taniyama M., Suzuki S. Correlation between the adiponectin-leptin ratio and parameters of insulin resistance in patients with type 2 diabetes. Metabolism 2005, 54:281-286.
124. Zaletel J., Barlovic D.P., Prezelj J. Adiponectin-leptin ratio: a useful estimate of insulin resistance in patients with type 2 diabetes. J Endocrinol Invest 2010, 33:514-518.
125. Xita N., Papassotiriou I., Georgiou I., Vounatsou M., Margeli A., Tsatsoulis A. The adiponectin-to-leptin ratio in women with polycystic ovary syndrome: relation to insulin resistance and proinflammatory markers. Metabolism 2007, 56:766-771.
126. Kumagai S., Kishimoto H., Masatakasuwa, Zou B., Harukasasaki The leptin to adiponectin ratio is a good biomarker for the prevalence of metabolic syndrome, dependent on visceral fat accumulation and endurance fitness in obese patients with diabetes mellitus. Metab Syndr Relat Disord 2005, 3:85-94.
127. Jardé T., Perrier S., Vasson M.P., Caldefie-Chézet F. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer 2010, 47:33-43.
128. Guadagni F., Roselli M., Martini F., Spila A., Riondino S., D'Alessandro R., et al. Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Res 2009, 29:3321-3327.
129. Chen D.C., Chung Y.F., Yeh Y.T., Chaung H.C., Kuo F.C., Fu O.Y., et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 2006, 237:109-114.
130. Gnacińska M., Małgorzewicz S., Guzek M., Lysiak-Szydłowska W., Sworczak K. Adipose tissue activity in relation to overweight or obesity. Endokrynol Pol 2010, 61:160-168.
131. Conroy S.M., Chai W., Lim U., Franke A.A., Cooney R.V., Maskarinec G. Leptin, adiponectin, and obesity among Caucasian and Asian women. Mediators Inflamm 2011, 2011:253580.
132. Hosoi T., Sasaki M., Miyahara T., Hashimoto C., Matsuo S., Yoshii M., et al. Endoplasmic reticulum stress induces leptin resistance. Mol Pharmacol 2008, 74:1610-1619.
133. Winnicki M., Puato M., Somers V.K., Zambon A., Marcovina S.M., Rattazzi M., et al. Leptin is associated with the size of the apolipoprotein(a) particle in African tribal populations living on fish or vegetarian diet. Atherosclerosis 2010, 211:303-307.
134. Hermsdorff H.H., Puchau B., Zulet M.A., Martínez J.A. Association of body fat distribution with proinflammatory gene expression in peripheral blood mononuclear cells from young adult subjects. OMICS 2010, 14:297-307.
135. Caimari A., Oliver P., Rodenburg W., Keijer J., Palou A. Slc27a2 expression in peripheral blood mononuclear cells as a molecular marker for overweight development. Int J Obes (Lond) 2010, 34:831-839.
136. Friebe D., Neef M., Kratzsch J., Erbs S., Dittrich K., Garten A., et al. Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia 2011, 54:1200-1211.
137. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
138. Jemal A., Center M.M., DeSantis C., Ward E.M. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010, 19:1893-1907.
139. Sedjo R.L., Byers T., Barrera E., Cohen C., Fontham E.T., Newman L.A., et al. A midpoint assessment of the American Cancer Society challenge goal to decrease cancer incidence by 25% between 1992 and 2015. CA Cancer J Clin 2007, 57:326-340.
140. Buijsse B., Feskens E.J., Schulze M.B., Forouhi N.G., Wareham N.J., Sharp S., et al. Fruit and vegetable intakes and subsequent changes in body weight in European populations: results from the project on diet, obesity, and genes (DiOGenes). Am J Clin Nutr 2009, 90:202-209.
141. Murthy N.S., Mukherjee S., Ray G., Ray A. Dietary factors and cancer chemoprevention: an overview of obesity-related malignancies. J Postgrad Med 2009, 55:45-54.
142. Ray A., Rogozina O.P., Bonorden M.J.L., Dogan S., Grande J.P., Cleary M.P. Prevention of obesity-related cancers: promising public health application from laboratory experience [Abstract]. Proceedings of the symposium on 'Marching Toward Cancer Prevention' (Mayo Clinic, Rochester, Minnesota; Mar 27-29, 2008) 2008.
143. Dirx M.J., Zeegers M.P., Dagnelie P.C., van den Bogaard T., van den Brandt P.A. Energy restriction and the risk of spontaneous mammary tumors in mice: a meta-analysis. Int J Cancer 2003, 106:766-770.